Summary of risk management plan for tramadol prolonged-release tablets (new formulation)

This is a summary of the risk management plan (RMP) for tramadol hydrochloride prolonged-release tablets. The RMP details important risks of tramadol prolonged-release tablets, how these risks can be minimised, and how more information will be obtained about tramadol hydrochloride's risks and uncertainties (missing information).

Tramadol hydrochloride's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how tramadol hydrochloride prolonged-release tablets should be used.

Important new concerns or changes to the current ones will be included in updates of tramadol hydrochloride's RMP.

I. The medicine and what it is used for

Tramadol hydrochloride prolonged-release tablets is authorised for treatment of moderate to severe pain (see SmPC for the full indication). It contains tramadol hydrochloride as the active substance and it is taken by mouth.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of tramadol hydrochloride prolonged-release tablets, together with measures to minimise such risks and the proposed studies for learning more about tramadol hydrochloride's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of tramadol hydrochloride prolonged-release tablets is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of tramadol hydrochloride prolonged-release tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of tramadol hydrochloride prolonged-release tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Convulsions (e.g. in patients with poorly controlled epilepsy) • Overdose • Dependence, withdrawal syndrome, tolerance, abuse • Concomitant use with anticoagulants • Serotonin syndrome during concomitant use with serotonergic drugs • Concomitant use with CNS depressants
Important potential risks	• Use in patients with a tendency of prolonged elimination (elderly above over 75 years or hepatic/renal impairment) • Use during pregnancy and breast-feeding
Missing information	• Use in paediatric population under 12 years of age

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of tramadol hydrochloride prolonged-release tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for tramadol hydrochloride prolonged-release tablets.